AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24132867 — intervention group
Group type: EXPERIMENTAL
Intervention: manualized dialectical-behavioral-therapy-based group psychotherapy (GPT) plus methylphenidate (MPH)
Number of subjects: 433
Study 24132867 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical management (CM) including supportive counseling plus methylphenidate (MPH)
Number of subjects: 433
Study 24132867 — intervention group
Group type: EXPERIMENTAL
Intervention: manualized dialectical-behavioral-therapy-based group psychotherapy (GPT) plus placebo (Plac)
Number of subjects: 433
Study 24132867 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical management (CM) including supportive counseling plus placebo (Plac)
Number of subjects: 433
Study 22342859 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR diagnosis of aneuploidy
Number of subjects: 71
Study 22342859 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR diagnosis of euploidy and aneuploidy
Number of subjects: 71
Study 20670909 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of virosomal-adjuvanted influenza vaccine (two doses of 0.50 mL 4 weeks apart)
Number of subjects: 65
Study 20670909 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of virosomal-adjuvanted influenza vaccine (two doses of 0.25 mL 4 weeks apart)
Number of subjects: 65
Study 17582488 — intervention group
Group type: EXPERIMENTAL
Intervention: Verb-Second clauses
Number of subjects: 19
Study 17582488 — intervention group
Group type: COMPARATOR
Intervention: Verb-Final clauses
Number of subjects: 19
Study 15257437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative facial monitoring
Number of subjects: 130
Study 15257437 — intervention group
Group type: COMPARATOR
Intervention: Surgery without intraoperative facial monitoring
Number of subjects: 130
Study 12063152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 50 weeks
Number of subjects: 395
Study 12063152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 38 weeks followed by 12 weeks of placebo
Number of subjects: 395
Study 12063152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 14 weeks followed by 36 weeks of placebo
Number of subjects: 395
Study 12063152 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 50 weeks
Number of subjects: 395
Study 9857626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 9857626 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 7614102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 255
Study 7614102 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 255
Study 2245435 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg od
Number of subjects: 30
Study 2245435 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil, 600 mg bid
Number of subjects: 30
Study 2245435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32861 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone (100 mg X 3)
Number of subjects: 81
Study 32861 — intervention group
Group type: COMPARATOR
Intervention: Thiothixene (10 mg X 3)
Number of subjects: 81
Study 30327398 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) after standard chemotherapy, delivered in 15 fractions of 3-4.5 Gy.
Number of subjects: 6
Study 30327398 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) after standard chemotherapy
Number of subjects: 6
Study 27101789 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate tissue adhesive
Number of subjects: 70
Study 27101789 — intervention group
Group type: COMPARATOR
Intervention: Standard suture
Number of subjects: 70
Study 24680712 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training regime
Number of subjects: 44
Study 24680712 — intervention group
Group type: COMPARATOR
Intervention: Low intensity training regime
Number of subjects: 44
Study 21787207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acitretin (approximately 25 mg/day)
Number of subjects: 0
Study 21787207 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acitretin (approximately 50 mg/day)
Number of subjects: 0
Study 21787207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20116091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mood condition (mood induction task)
Number of subjects: 38
Study 20116091 — intervention group
Group type: COMPARATOR
Intervention: Previous history of self-harm behaviour
Number of subjects: 38
Study 18612882 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 86
Study 16078955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobblestone mat walking
Number of subjects: 108
Study 16078955 — intervention group
Group type: COMPARATOR
Intervention: Regular walking
Number of subjects: 108
Study 12575301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengzhanhua injection (Group A)
Number of subjects: 100
Study 12575301 — intervention group
Group type: COMPARATOR
Intervention: Fufangdanshen injection (Group B)
Number of subjects: 100
Study 10559515 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with SI (epsilon(4)/(3) genotype)
Number of subjects: 166
Study 10559515 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients without SI
Number of subjects: 166
Study 10559515 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with SI (epsilon(4) allele)
Number of subjects: 166
Study 10559515 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with epsilon(4)/(3)epsilon(4)/(4) genotype
Number of subjects: 166
Study 10559515 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals without SI)
Number of subjects: 166
Study 10559515 — intervention group
Group type: COMPARATOR
Intervention: NIDDM without SI
Number of subjects: 166
Study 8528732 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 2210
Study 8528732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2210
Study 1906472 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative blood salvage
Number of subjects: 109
Study 1906472 — intervention group
Group type: COMPARATOR
Intervention: Banked blood
Number of subjects: 109
Study 6420046 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum and chemotherapy (C + I)
Number of subjects: 93
Study 6420046 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (C)
Number of subjects: 93
Study 31277623 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app intervention (n = 54)
Number of subjects: 108
Study 31277623 — intervention group
Group type: COMPARATOR
Intervention: Regular intervention for caregivers (n = 54)
Number of subjects: 108
Study 28789317 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory scaled system with randomly varying subapertures
Number of subjects: 0
Study 28789317 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machine based lucky imaging and non-negative matrix factorization based multiframe blind deconvolution
Number of subjects: 0
Study 28789317 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling of the experimental system
Number of subjects: 0
Study 26485234 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-Assisted Multicomponent Behavioral Intervention
Number of subjects: 0
Study 26485234 — intervention group
Group type: COMPARATOR
Intervention: Attention-controlled HIV/STI health education and counseling
Number of subjects: 0
Study 25034347 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-advertisement
Number of subjects: 1269
Study 25034347 — intervention group
Group type: COMPARATOR
Intervention: Control advertisement
Number of subjects: 1269
Study 22683707 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 90
Study 22683707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (BupTAP)
Number of subjects: 90
Study 22683707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Clonidine (CloTAP)
Number of subjects: 90
Study 20486208 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop intervention (2.04 mg XN, 1.20 mg IX, and 0.1 mg 8‐PN per supplement)
Number of subjects: 21
Study 20486208 — intervention group
Group type: COMPARATOR
Intervention: Control (no hop supplements)
Number of subjects: 21
Study 17509999 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone and mail survey
Number of subjects: 897
Study 16160648 — intervention group
Group type: EXPERIMENTAL
Intervention: QGS
Number of subjects: 20
Study 16160648 — intervention group
Group type: EXPERIMENTAL
Intervention: ECTb
Number of subjects: 20
Study 16160648 — intervention group
Group type: EXPERIMENTAL
Intervention: LVGTF
Number of subjects: 20
Study 16160648 — intervention group
Group type: EXPERIMENTAL
Intervention: LMC
Number of subjects: 20
Study 11807724 — intervention group
Group type: EXPERIMENTAL
Intervention: AC polysaccharide (MACP) vaccine
Number of subjects: 0
Study 11807724 — intervention group
Group type: EXPERIMENTAL
Intervention: C conjugate (MCC) vaccine
Number of subjects: 0
Study 11807724 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide antigens (MACP and MCC)
Number of subjects: 0
Study 10417495 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg twice daily)
Number of subjects: 12
Study 10417495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7734997 — intervention group
Group type: EXPERIMENTAL
Intervention: One blood sample for total cholesterol (TC) level determination
Number of subjects: 142
Study 7734997 — intervention group
Group type: EXPERIMENTAL
Intervention: Average of two blood samples for total cholesterol (TC) level determination
Number of subjects: 142
Study 1914366 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 0
Study 1914366 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg aspirin with 64 mg caffeine
Number of subjects: 0
Study 1914366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6312791 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy polysaccharide (25 g/day)
Number of subjects: 14
Study 6312791 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber basal diet (control)
Number of subjects: 14
Study 6312791 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy polysaccharide added to glucose solution
Number of subjects: 14
Study 30664550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 127
Study 30664550 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Care (SC)
Number of subjects: 127
Study 27769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic Syndrome (MetS)
Number of subjects: 5398
Study 27769610 — intervention group
Group type: COMPARATOR
Intervention: No Metabolic Syndrome (Control)
Number of subjects: 5398
Study 27769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (component of MetS)
Number of subjects: 5398
Study 27769610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (component of MetS)
Number of subjects: 5398
Study 26900640 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD)
Number of subjects: 40
Study 26900640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 40
Study 25100134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day on a 4-week-on-2-week-off schedule
Number of subjects: 292
Study 25100134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day continuous dosing
Number of subjects: 292
Study 25100134 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-1α low (percent of tumor expression groups 0-2)
Number of subjects: 292
Study 25100134 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-1α high (percent of tumor expression groups 3-4)
Number of subjects: 292
Study 25100134 — intervention group
Group type: COMPARATOR
Intervention: VHL inactivation mechanisms (mutation, methylation, large deletion)
Number of subjects: 292
Study 18254988 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 11716
Study 18254988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11716
Study 15121558 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 3
Study 15121558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 microg)
Number of subjects: 3
Study 15121558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 3
Study 11049006 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g x kg(‐1) ethanol (EOH) in young subjects
Number of subjects: 18
Study 11049006 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg diazepam (DZ) in young subjects
Number of subjects: 18
Study 11049006 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g x kg(‐1) ethanol (EOH) in older subjects
Number of subjects: 18
Study 11049006 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam (DZ) in older subjects
Number of subjects: 18
Study 9313702 — intervention group
Group type: EXPERIMENTAL
Intervention: lexipafant (100 mg/day by continuous intravenous infusion for up to 7 days)
Number of subjects: 50
Study 9313702 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 12959281 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg oral dose)
Number of subjects: 14
Study 12959281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3552216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide and hydrocortisone
Number of subjects: 286
Study 3552216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 30861038 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AFO provision (week 1)
Number of subjects: 33
Study 30861038 — intervention group
Group type: COMPARATOR
Intervention: Delayed AFO provision (week 9)
Number of subjects: 33
Study 28920183 — intervention group
Group type: EXPERIMENTAL
Intervention: Regularly prescribed medications (average 5.6 medications per patient)
Number of subjects: 503
Study 28920183 — intervention group
Group type: EXPERIMENTAL
Intervention: CIRS-G index measures
Number of subjects: 503
Study 28920183 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (defined as five or more concurrent medications)
Number of subjects: 503
Study 26588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg daily with RT plus TMZ and post-RT TMZ
Number of subjects: 26
Study 26588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg daily
Number of subjects: 26
Study 26588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg daily
Number of subjects: 26
Study 26588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent treatment arm
Number of subjects: 26
Study 26588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance arm
Number of subjects: 26
Study 26588662 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 26
Study 24388483 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eating speed
Number of subjects: 70
Study 24388483 — intervention group
Group type: COMPARATOR
Intervention: Fast eating speed
Number of subjects: 70
Study 23099357 — intervention group
Group type: EXPERIMENTAL
Intervention: MT plus LCSD
Number of subjects: 15
Study 23099357 — intervention group
Group type: COMPARATOR
Intervention: MT alone
Number of subjects: 15
Study 23099357 — intervention group
Group type: EXPERIMENTAL
Intervention: LCSD
Number of subjects: 15
Study 19229603 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine therapy initiated at the time of hospital admission
Number of subjects: 1270
Study 19229603 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine therapy
Number of subjects: 1270
Study 19229603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1270
Study 17437798 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance bacillus Calmette-Guerin
Number of subjects: 501
Study 17437798 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 501
Study 17437798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystectomy for T2 or greater disease
Number of subjects: 501
Study 15046281 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition admixtures exposed to ambient light for 24 hours
Number of subjects: 54
Study 15046281 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition admixtures protected from ambient light for 24 hours
Number of subjects: 54
Study 15046281 — intervention group
Group type: COMPARATOR
Intervention: Serum MDA concentrations in orally fed healthy neonates
Number of subjects: 54
Study 11913007 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weekly sessions about healthy eating followed by 6 weekly sessions about exercise
Number of subjects: 0
Study 11913007 — intervention group
Group type: COMPARATOR
Intervention: 6 weekly sessions about exercise followed by 10 weekly sessions about healthy eating
Number of subjects: 0
Study 11913007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 0
Study 9522325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-levonorgestrel group: 2 mg estradiol valerate (days 1-21) + 0.25 mg levonorgestrel (days 12-21)
Number of subjects: 210
Study 9522325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-levonorgestrel group: 2 mg estradiol valerate (days 1-21) + 0.15 mg levonorgestrel (days 10-21)
Number of subjects: 210
Study 9522325 — intervention group
Group type: EXPERIMENTAL
Intervention: High-levonorgestrel group
Number of subjects: 210
Study 9522325 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-levonorgestrel group
Number of subjects: 210
Study 9522325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study 7526050 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 516
Study 7526050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 3117490 — intervention group
Group type: EXPERIMENTAL
Intervention: NORPLANT implants (first set)
Number of subjects: 376
Study 3117490 — intervention group
Group type: EXPERIMENTAL
Intervention: NORPLANT implants (replacement set)
Number of subjects: 376
Study 29667091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-scope channel stent release technique
Number of subjects: 41
Study 29667091 — intervention group
Group type: COMPARATOR
Intervention: Extra-scope channel release technique
Number of subjects: 41
Study 27903282 — intervention group
Group type: EXPERIMENTAL
Intervention: START NOW skills training programme (12-week duration)
Number of subjects: 128
Study 27903282 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 128
Study 27903282 — intervention group
Group type: EXPERIMENTAL
Intervention: START NOW skills training programme
Number of subjects: 128
Study 24578074 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth decision-support system (mHealth DSS) for guideline-based screening and management of tobacco use
Number of subjects: 14115
Study 23759041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal examination (n = 61)
Number of subjects: 135
Study 23759041 — intervention group
Group type: COMPARATOR
Intervention: No vaginal examination (n = 74)
Number of subjects: 135
Study 20961748 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Number of subjects: 10
Study 20961748 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound therapy
Number of subjects: 10
Study 18482017 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer with DNA repair enzymes (Advanced Night Repair Concentrate)
Number of subjects: 0
Study 18482017 — intervention group
Group type: COMPARATOR
Intervention: Untreated UV-irradiated subjects
Number of subjects: 0
Study 17286119 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar faces presented as internal features
Number of subjects: 0
Study 17286119 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar faces presented as internal features
Number of subjects: 0
Study 17286119 — intervention group
Group type: COMPARATOR
Intervention: Whole faces (both familiar and unfamiliar)
Number of subjects: 0
Study 12654939 — intervention group
Group type: EXPERIMENTAL
Intervention: JPP trials
Number of subjects: 28
Study 12654939 — intervention group
Group type: COMPARATOR
Intervention: JCCP trials
Number of subjects: 28
Study 12654939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both journals
Number of subjects: 28
Study 11225746 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (Humalog)
Number of subjects: 62
Study 11225746 — intervention group
Group type: COMPARATOR
Intervention: Buffered regular human insulin (Velosulin)
Number of subjects: 62
Study 8962558 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 21
Study 8962558 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 21
Study 1444555 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/kg 20% albumin
Number of subjects: 60
Study 1444555 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml/kg 4.5% albumin
Number of subjects: 60
Study 1444555 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml/kg fresh frozen plasma
Number of subjects: 60
Study 3989147 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior rhinomanometry
Number of subjects: 10
Study 3989147 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior rhinomanometry
Number of subjects: 10
Study 3989147 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced oscillation rhinomanometry
Number of subjects: 10
Study 3989147 — intervention group
Group type: COMPARATOR
Intervention: Conventional rhinomanometric techniques
Number of subjects: 10
Study 29727479 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 0.4 mg/kg per week
Number of subjects: 102
Study 29727479 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin (CyA) 4 mg/kg per day
Number of subjects: 102
Study 27553723 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere anodal-excitatory tDCS
Number of subjects: 12
Study 27553723 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere cathodal-inhibitory tDCS
Number of subjects: 12